-
Otolaryngology and Head and Neck Surgery 1979
Topics: Bleomycin; Drug Therapy, Combination
PubMed: 92001
DOI: 10.1177/019459987908700401 -
Cellular Physiology and Biochemistry :... 2017Bleomycin is a clinically used anti-cancer drug that produces DNA breaks once inside of cells. However, bleomycin is a positively charged molecule and cannot get inside...
BACKGROUND/AIMS
Bleomycin is a clinically used anti-cancer drug that produces DNA breaks once inside of cells. However, bleomycin is a positively charged molecule and cannot get inside of cells by free diffusion. We previously reported that the cell surface negatively charged glycosaminoglycans (GAGs) may be involved in the cellular uptake of bleomycin. We also observed that a class of positively charged small molecules has Golgi localization once inside of the cells. We therefore hypothesized that bleomycin might perturb Golgi-operated GAG biosynthesis.
METHODS
We used stable isotope labeling coupled with LC/MS analysis of GAG disaccharides simultaneously from bleomycin-treated and non-treated cancer cells. To further understand the cytotoxicity of bleomycin and its relationship to GAGs, we used sodium chlorate to inhibit GAG sulfation and commercially available GAGs to compete for cell surface GAG/bleomycin interactions in seven cell lines including CHO745 defective in both heparan sulfate and chondroitin sulfate biosynthesis.
RESULTS
we discovered that heparan sulfate GAG was significantly undersulfated and the quantity and disaccharide compositions of GAGs were changed in bleomycin-treated cells in a concentration- and time-dependent manner. We revealed that bleomycin-induced cytotoxicity was directly related to cell surface GAGs.
CONCLUSION
GAGs were targeted by bleomycin both at cell surface and at Golgi. Thus, GAGs might be the biological relevant molecules that might be related to the bleomycin-induced fibrosis in certain cancer patients, a severe side effect with largely unknown molecular mechanism.
Topics: Animals; Antipyrine; Bleomycin; CHO Cells; Chondroitin Sulfates; Chromatography, High Pressure Liquid; Cricetinae; Cricetulus; Deuterium; Edaravone; HCT116 Cells; HT29 Cells; Heparitin Sulfate; Humans; Isotope Labeling; Mass Spectrometry
PubMed: 28982096
DOI: 10.1159/000481763 -
Cancer Chemotherapy and Biological... 1999
Review
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Humans; Pulmonary Fibrosis
PubMed: 10800476
DOI: No ID Found -
Cancer Chemotherapy and Biological... 1997
Review
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Drug Resistance, Neoplasm; Humans; Pulmonary Fibrosis
PubMed: 9551207
DOI: No ID Found -
Mutation Research Mar 1991
Review
Topics: Animals; Bleomycin; Carcinogens; Chromosomes; DNA Damage; Humans; Mutagenesis; Mutagens
PubMed: 1706477
DOI: 10.1016/0165-1110(91)90022-n -
Seminars in Oncology Apr 1992Bleomycin is a cell-cycle--specific chemotherapeutic agent, with several interesting properties, that lends itself to use in combination chemotherapeutic protocols,... (Review)
Review
Bleomycin is a cell-cycle--specific chemotherapeutic agent, with several interesting properties, that lends itself to use in combination chemotherapeutic protocols, especially those for malignant lymphomas. In the following article, bleomycin's use as a single agent and subsequently in three generations of combination chemotherapeutic regimens is reviewed. Bleomycin's lack of myelosuppression and its tendency to concentrate in lymphoid tissue while maintaining tolerable toxicities has been the rationale for its incorporation into more aggressive treatment regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Protocols; Humans; Lymphoma, Non-Hodgkin
PubMed: 1384144
DOI: No ID Found -
Dermatologic Surgery : Official... Oct 2008Intralesional bleomycin has been favorably used off-label to treat various skin conditions. These include warts, hemangiomas, vascular malformations, telangiectasias,... (Review)
Review
Intralesional bleomycin has been favorably used off-label to treat various skin conditions. These include warts, hemangiomas, vascular malformations, telangiectasias, several types of cutaneous malignancies, condyloma acuminata, and the lesions of leishmaniasis cutis. Currently, there is a limited amount of evidence from randomized placebo-controlled trials comparing intralesional bleomycin with other local treatments for these disorders. In this article, we review the pharmacodynamics, mechanism of action, safety profile, and clinical applications of intralesional bleomycin. Dosages, techniques for administration, and efficacy of intralesional bleomycin for each aforementioned clinical entity are also provided. Given its ease and safety in administration, efficacy, and availability, off-label use of intralesional bleomycin can be considered another primary and/or adjunctive therapy for various common cutaneous conditions by practitioners in dermatology today.
Topics: Antibiotics, Antineoplastic; Bleomycin; Humans; Injections, Intralesional; Skin Diseases
PubMed: 18616538
DOI: 10.1111/j.1524-4725.2008.34281.x -
Journal of the American Podiatric... 2006Sixty-two patients were treated for single or multiple warts by intralesional injection of bleomycin sulfate (1.5 U/mL) and then were observed for 6 months. The dose... (Clinical Trial)
Clinical Trial
Sixty-two patients were treated for single or multiple warts by intralesional injection of bleomycin sulfate (1.5 U/mL) and then were observed for 6 months. The dose varied according to the size of the lesion and ranged from 0.25 to 1.0 mL per injection per lesion, up to a maximum dose of 3 mL. The total cure rate was 87% after one or two injections. Twelve of the 62 patients required a second injection.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Bleomycin; Dose-Response Relationship, Drug; Female; Foot Dermatoses; Humans; Injections, Intralesional; Male; Middle Aged; Treatment Outcome; Warts
PubMed: 16707633
DOI: 10.7547/0960220 -
Head & Neck Surgery 1981Bleomycin (Blenoxane) and cisplatin (Platinol) are two anticancer drugs with activity for head and neck tumors. Introduced into clinical use in the past ten years,... (Review)
Review
Bleomycin (Blenoxane) and cisplatin (Platinol) are two anticancer drugs with activity for head and neck tumors. Introduced into clinical use in the past ten years, bleomycin is used primarily in the chemotherapy of squamous cell carcinomas, lymphomas, and testicular carcinoma, while cisplatin is effective against testicular and ovarian carcinoma, head and neck cancer, bladder cancer, and neuroblastoma. Bleomycin is rapidly excreted renally (T 1/2 beta = 2-4 hr) although enzymatic inactivation also occurs in many tissues. Cisplatin is nonenzymatically converted to highly protein-bound metabolites, which then undergo renal elimination, but total body clearance occurs much more slowly than with bleomycin (T 1/2 beta = 40-50 hr). Both agents have acute and chronic toxicities; the acute toxicities are generally reversible but cause a great deal of patient discomfort, while the chronic toxicities are often irreversible and dose-limiting. For bleomycin, the acute toxicities are mucocutaneous and pyretic, while severe nausea and vomiting represent the major acute toxicities of cisplatin therapy. Cumulative dose-related pulmonary toxicity is the most serious chronic toxicity of bleomycin. The clinical, radiographic, and pathologic presentations are nonspecific, although identification of high-risk patients may be possible with serial pulmonary function tests. Cumulative nephrotoxicity occurs with cisplatin use and its incidence and severity can be reduced by maintaining adequate hydration and diuresis during and following administration of the drug.
Topics: Aged; Bleomycin; Cisplatin; Digestive System; Fever; Humans; Kinetics; Lung; Mucous Membrane; Skin
PubMed: 6171547
DOI: 10.1002/hed.2890040204 -
Archives of Dermatology Feb 1991A multiple puncture technique using a bifurcated vaccination needle to introduce bleomycin sulfate (1 U/mL sterile saline solution) into warts resulted in elimination of...
A multiple puncture technique using a bifurcated vaccination needle to introduce bleomycin sulfate (1 U/mL sterile saline solution) into warts resulted in elimination of 92% of a random series of 258 warts after a single treatment. Recurrence was not observed during a 6-month follow-up period. Six of the 66 patients required two to seven treatments for wart eradication, and four patients requested alternative therapy after initial failure with a single bleomycin treatment.
Topics: Adolescent; Adult; Bleomycin; Child; Child, Preschool; Female; Humans; Injections, Intralesional; Male; Middle Aged; Skin Diseases; Warts
PubMed: 1703756
DOI: No ID Found